Full-Time
Dental Assistant
M42
10,001+ employees
Integrated healthcare provider leveraging AI genomics
No salary listed
Abu Dhabi - United Arab Emirates
In Person
Bachelor's, Associate's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to M42
See people who can refer or advise you
- A Bachelor's degree in Dental Surgery or Nursing, or a Diploma in Dental Assisting, Dental Nursing, Dental Hygiene, or a related field.
- A valid Department of Health, Ministry of Health, or Dubai Health Authority license as a Dental Assistant, or eligibility to obtain one.
- Relevant clinical experience in a dental healthcare setting, where applicable.
- Knowledge of dental procedures, infection control, and patient safety standards.
- Strong communication skills, proficiency in Microsoft Office, and fluency in English.
- Provide chairside assistance to dentists during examinations, treatments, and specialized dental procedures, ensuring the delivery of safe and high-quality patient care.
- Prepare, clean, sterilize, and maintain dental instruments, equipment, and clinical areas in accordance with infection prevention and control standards.
- Ensure treatment rooms are fully prepared before patient appointments and efficiently restored following procedures.
- Support patient preparation and provide appropriate pre- and post-treatment guidance to enhance the patient experience.
- Maintain accurate patient records, clinical documentation, and appointment information in compliance with organizational and regulatory requirements.
- Adhere to M42, Department of Health, and applicable healthcare quality, safety, and infection control policies and procedures.
- Facilitate efficient patient flow by coordinating with clinicians and administrative teams to support seamless clinic operations.
- Collaborate effectively with dentists and multidisciplinary healthcare professionals to deliver patient-centered care and achieve clinical excellence.
M42 operates a global network of hospitals, specialty clinics, and diagnostic centers across 26 countries, formed in 2023 from the merger of G42 Healthcare and Mubadala Health. It combines clinical care with genomics, biobanking, and digital health platforms to enable precision, preventive, and patient-centered care. Revenue comes from clinical services, diagnostics, health programs, and government contracts for large-scale digital health platforms like Malaffi and the Emirati Genome Programme, reflecting a vertically integrated model that embeds data and technology into care for B2C, B2G, and B2B customers. The goal is to raise healthcare quality and accessibility and to advance predictive medicine by linking traditional care with genomics, diagnostics, and digital health.
Company Size
10,001+
Company Stage
N/A
Total Funding
N/A
Headquarters
Abu Dhabi, United Arab Emirates
Founded
2022
Get referred to M42
See people who can refer or advise you
Simplify's Take
What believers are saying
- June 2026 biobank expansion and Mammoth partnership deepen M42's precision-medicine pipeline.
- RASID analyzed 75,000 wastewater samples by September 2026, proving scalable population surveillance.
- M42's August 2026 Botswana entry opens a decade-long platform for digital health export.
What critics are saying
- Botswana and Bahrain deals depend on government execution; delays hit revenue and credibility by 2027.
- Oracle Health, BioTwin, and Mammoth Biosciences can commoditize M42's AI and genomics edge.
- If Abu Dhabi policy shifts, M42 loses access to the Emirati Genome Programme moat.
What makes M42 unique
- M42 combines Abu Dhabi Biobank, Malaffi, genomics, and care delivery under one operator.
- Its 2025 platform restructure centralizes Global Patient Care, Digital Health, and AI Life Sciences.
- M42 turns sovereign-backed healthcare into a regulated data-and-clinical stack across 26 countries.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↑ 18%1 year growth
↑ 18%2 year growth
↑ 0%M42 makes ADIHEX debut, spotlighting environmental intelligence. WAM 04 Sep 2026, 16:06 GMT+ ABU DHABI, 4th September, 2026 (WAM) - M42, a global health leader powered by artificial intelligence (AI), technology and genomics, is participating for the first time at the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX), taking place until 6th September 2026 at ADNEC Centre Abu Dhabi. At ADIHEX, M42 is spotlighting its growing work in environmental intelligence and how advanced science, AI and data can generate insights that support public health, environmental resilience and community wellbeing. At the centre of M42's participation is RASID, an AI-powered platform that measures a city's health by transforming wastewater sample analysis into hyper-localised and predictive city health intelligence. Developed in partnership with the Abu Dhabi Quality and Conformity Council (ADQCC), the platform is designed to help authorities detect emerging public health risks through wastewater analysis across 100 testing sites in Abu Dhabi, predictive analytics and AI-supported insights that inform data-driven decision-making. Eng. Abdulla Hassan Al Muaini, Executive Director - Central Testing Laboratory, said, "Strengthening Abu Dhabi's quality infrastructure means continually evolving how we understand and respond to the factors that shape community wellbeing and quality of life. Through our work with M42 on RASID, we are bringing together complementary expertise in environmental monitoring, science and technology. ADIHEX is an opportunity to demonstrate the value of this collaborative approach and its contribution to a healthier, safer and more resilient Abu Dhabi." Operational since 2022, the RASID Laboratory has analyzed more than 75,000 wastewater samples across the UAE, covering more than 400 chemical and biological analytes. This work has created one of the region's largest wastewater surveillance datasets, offering a clearer view of public health, environmental quality and community trends. Dimitris Moulavasilis, Group Chief Executive Officer, M42, said, "Our environment tells us a great deal about the health and wellbeing of our communities. By interpreting these signals, we can generate actionable intelligence that supports earlier, more informed decision making. At ADIHEX, we are demonstrating how the full power of M42's intelligence infrastructure and capabilities can advance human, animal and environmental health to support the UAE's growth, resilience and prosperity." Unlike traditional environmental monitoring, which typically provides a snapshot at a particular point in time, RASID is designed for continuous, population-level monitoring. Its AI models analyse large wastewater datasets to determine a city's health by creating an AI-generated risk score for all threats, use predictive analytics to forecast risk and support with source identification to help channel resources and response. Visitors can explore M42's environmental intelligence capabilities at Stand A-001 & A-003, located in the Preservation of Environment & Cultural Heritage section at ADIHEX 2026. In addition to RASID, M42 will also be showcasing its other capabilities that are advancing innovation in health for people and the planet, including specialist clinical care, genomics and digital health.
Abu Dhabi uses AI to spot potential health risks through wastewater monitoring. September 4, 2026 75,000 samples later, Abu Dhabi's AI wastewater system tracks health risks. Abu Dhabi: Wastewater collected across Abu Dhabi is being analysed using artificial intelligence to help authorities detect potential public health and environmental risks before they escalate. The technology, known as RASID, analyses wastewater samples from 100 testing sites across Abu Dhabi and combines the data with AI and predictive analytics to provide authorities with insights into community health trends. M42 is showcasing the platform for the first time at the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026, which is taking place at ADNEC Centre Abu Dhabi through September 6. Developed in partnership with the Abu Dhabi Quality and Conformity Council (ADQCC), RASID has been operational since 2022. Its laboratory has analysed more than 75,000 wastewater samples collected across the UAE, monitoring over 400 chemical and biological indicators. The data can provide insights into public health, environmental conditions and emerging trends within communities. How does it work? Rather than relying on individual environmental readings, RASID continuously monitors wastewater at the population level. AI models analyse large volumes of data collected from wastewater samples and generate risk scores for identified threats. Predictive analytics can then be used to forecast potential risks and help identify their possible sources, enabling authorities to better anticipate where resources may be needed. Dimitris Moulavasilis, Group Chief Executive Officer of M42, said environmental data could provide valuable insights into the health of communities. "By interpreting these signals, we can generate actionable intelligence that supports earlier and more informed decision-making," he said. 100 testing sites. Abdulla Hassan Al Muaini, Executive Director of the Central Testing Laboratory, said the partnership brings together environmental monitoring, science and technology. "Through our work with M42 on RASID, we are bringing together complementary expertise in environmental monitoring, science and technology," he said. M42 said the wastewater surveillance programme has created one of the region's largest datasets of its kind. Alongside RASID, the company is showcasing its work in genomics, digital health and specialised clinical care during its first participation at ADIHEX.
M42 expands international presence in Africa with Botswana health partnership. * Wednesday, August 26, 2026 5:14PM * 3 minutes Reading * Summary * A+ GABORONE, 26th August, 2026 (WAM) - M42, the global health leader powered by artificial intelligence (AI), technology and genomics, today announced its entry into Africa with a significant 10-year strategic partnership with the Ministry of Health of Botswana. The agreement, signed in Gaborone, Botswana's capital, marks M42's first health systems partnership in Africa and a defining step in the company's international expansion. The agreement was signed on behalf of the Government of Botswana by Acting Permanent Secretary Dr. Tshepo Machacha, in the presence of the Minister of Health Dr. Stephen Modise, and Kareem Shahin, Chief Executive Officer of M42's Digital Health Solutions platform and Group Chief Digital Officer. The partnership is anchored in a decade-long commitment that will see M42 partner with Botswana on digital health transformation, a national genomics programme, precision medicine and local and regional capacity development. The partnership will also involve M42 and Mubadala Bio, a life sciences company, working together with Botswana on the supply of pharmaceutical and medical equipment to help build a reliable and sustainable medical supply chain, enabling better access for the people of Botswana, and a more efficient and timely procurement process across the country. The signing comes shortly after the Botswana Parliament's approval of the National Health Insurance Policy on 19th August 2026 presented by Dr. Modise to achieve Universal Health Coverage (UHC), guaranteeing equitable and affordable medical care for all citizens regardless of income or geographic location. The agreement between Botswana and M42 is comprehensive in scope, aligning Botswana's national healthcare agenda with M42's proven strengths in clinical care, genomics, digital health, AI and capacity development. This enables M42 to contribute meaningfully to the long-term transformation of the country's health system and help deliver meaningful impact for the people of Botswana, working in partnership with the country's Ministry of Health to pave the way for a stronger, more responsive and sustainable healthcare system. Dr. Stephen Modise, BotswanaMinister of Health of Botswana, said, "This agreement is about strengthening our health security, building resilience into our supply chains, and ensuring that no patient in Botswana is left without the medicines and medical products they need because of avoidable delays. Through this partnership, we are opening a reliable gateway to medicines, medical supplies and health products whenever and wherever the country needs them." Commenting on the agreement, Dimitris Moulavasilis, Group Chief Executive of M42, said, "M42 has been accelerating our efforts to showcase our healthcare capabilities across the Global South, where we see a distinct opportunity for nations to leapfrog legacy systems and build digital and AI native health systems that are prevention first. This agreement marks our entry into Africa and presents an opportunity to deploy our full capabilities across digital health transformation, genomics, precision medicine and capacity development to help serve the people of Botswana in partnership with the country's Ministry of Health." Kareem Shahin, Chief Executive Officer, Digital Health Solutions Platform and Group Chief Digital Officer of M42, added, " It is a privilege to stand alongside the Ministry of Health of Botswana as a long-term partner in the country's health transformation. We support the Ministry's commitment to a health system that every citizen can rely on, where medicines are available, technologies work and care reaches every community. We look forward to working side by side with the Ministry and with Botswana's health professionals to help make that vision a reality, and to advancing the health and well-being of the people of Botswana." By combining a resilient medical supply chain with cooperation across digital health, genomics, and precision medicine, the partnership reflects a shared commitment to building a health system that serves Botswana's people today and for generations to come. * Health * United Arab Emirates (UAE) * BOTSWANA (BWA) Also available in the following languages:
Strengthening cooperation between Tamkeen and M42 through a number of strategic initiatives in the healthcare sector and launching Amanah Academy Wednesday, July 22, 2026 * The partnership includes exploring several capacity-building initiatives in the healthcare sector focusing on skills development, job creation, and innovation in the health sector * Launching Amanah Academy as a specialized simulation-based training center within the facility Tamkeen and M42, a global leader in AI-powered health, modern technologies, and genomics, announced the signing of a memorandum of understanding to explore areas of joint cooperation in creating promising opportunities for Bahraini talents and innovation in the sector. This cooperation aims to provide a number of training opportunities for doctors working at Amanah Healthcare facility, launch Amanah Academy - a specialized simulation-based training center within the facility - in addition to launching a set of digital initiatives in the public health sector, including an AI-powered clinical assistant and a dedicated patient application. The cooperation with Tamkeen aligns with the strategic priorities of the Labor Fund for 2026, which focus on areas with the highest returns for the economy and Bahrainis, contributing to initiatives that link skills with available job opportunities in the market, adopting an innovative approach to stimulate private sector growth and financing, as well as developing mechanisms, enhancing governance, and institutional culture at the fund. Amanah Academy is scheduled to open in the fourth quarter of 2026 and will include a lecture hall, several classrooms, and a simulation training wing for applied learning. In its first phase, the academy will support the development of Amanah Healthcare - Bahrain employees, with its activities later expanding to include specialist and allied healthcare professionals across the kingdom. This partnership strengthens the existing cooperation between Tamkeen and M42 in Bahrain by supporting the private sector, enhancing training, employment, and skills development opportunities for Bahraini citizens, and improving the quality and accessibility of health services through national capacity building and adoption of modern technologies. Amanah Academy is the first planned initiative under this partnership, aimed at delivering tangible results for healthcare workers and supporting the growth of the health sector in Bahrain. These initiatives include a program to increase the Bahrainization rate at Amanah Healthcare - Bahrain and support the development of national competencies, as well as a program to support the qualification, training, and career development of general practitioners, in addition to other initiatives to expand job opportunities and develop specialized skills in the healthcare sector. Commenting on the announcement, Her Excellency Ms. Maha Abdul Hamid Mofeez, Chief Executive of Tamkeen, said: "Through our cooperation with M42, we aim to empower Bahrainis in the healthcare sector to acquire the required specialized skills, while supporting their employment and career development, contributing to building qualified national cadres capable of keeping pace with sector developments. It also reflects Tamkeen's commitment to working with strategic partners to provide quality opportunities that contribute to sustainable growth and enhance the competitiveness of national competencies, supporting the Kingdom of Bahrain's directions in developing the health sector and raising its efficiency." For his part, Dr. Mohamed Amin Al-Saati, CEO of M42 Bahrain, said: "We express our deep appreciation to His Highness Sheikh Isa bin Salman bin Hamad Al Khalifa, Minister of the Cabinet Affairs and Chairman of the Board of Directors of Tamkeen, for the important role Tamkeen plays in supporting Bahraini competencies by providing employment, training, and professional development opportunities in vital and high-demand sectors. We also extend our sincere appreciation to His Excellency Lieutenant General Doctor Sheikh Mohammed bin Abdullah Al Khalifa, Chairman of the Supreme Council of Health, for his pivotal role in developing the health sector in Bahrain and enhancing the integration and quality of health services." He added: "This announcement reflects the importance of public-private partnerships in achieving sustainable institutional impact, and embodies the shared commitment between the Kingdom of Bahrain and the sisterly United Arab Emirates to elevate the health sector, develop national competencies, and achieve sustainable impact at the regional level. Through Amanah Academy, we are working to transfer the proven health expertise that M42 has developed over years in Abu Dhabi, aiming to create a platform that places national capacity building at the core of its priorities. With our trusted partner Tamkeen, we look forward to empowering Bahraini competencies and achieving tangible national impact in line with Bahrain Vision 2030." This announcement comes as a continuation of the existing cooperation between Tamkeen and M42 in Bahrain, including Tamkeen's support for Amanah Healthcare - Bahrain, the first facility of its kind for long-term post-acute rehabilitative care, established through a strategic partnership between Mumtalakat Holding Company (Mumtalakat) and M42, and plans to employ over 300 Bahrainis, contributing to supporting national competencies and strengthening the healthcare sector in the kingdom. To learn more about the partnership between Tamkeen and M42 in Bahrain and get the latest updates on its initiatives, follow Tamkeen on Instagram @tamkeenbahrain or Amanah Healthcare - Bahrain on Instagram @amanahealthcarebh.
Abu Dhabi Biobank, BioTwin announce strategic partnership to expand Human Virtual Twin technology in UAE. WAM 26 Jun 2026, 15:51 GMT+ SAN DIEGO, USA, 26th June, 2026 (WAM) - Abu Dhabi Biobank, a strategic initiative between the Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and global health leader M42, announced a strategic partnership with BioTwin to expand the deployment of their AI-based Virtual Human Twin technology focusing on early detection, prevention and precision health in Abu Dhabi. Announced on the sidelines of BIO International Convention 2026 in San Diego, USA, this partnership combines BioTwin's longitudinal biomarker platform and Virtual Human Twin technology with Abu Dhabi Biobank's ability to connect biological data with genomic, clinical, and AI-driven insights to decode complex diseases, accelerate clinical research, and shift care from reactive to proactive. The collaboration aims to accelerate the translation of advanced health data into early signals, prevention strategies and more personalized care, with the first application focusing on multi-cancer screening. Abu Dhabi has established itself as a leading hub for health innovation, advanced clinical infrastructure, biobanking, genomics, research and real-world implementation. Through this collaboration, BioTwin and Abu Dhabi Biobank aim to contribute to that ecosystem by advancing a scalable model for early detection and preventive precision health. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi, said: "Abu Dhabi has successfully built a global living lab for intelligent life sciences. By connecting population-scale genomics, advanced longitudinal health data, and real-world evidence with agile regulation, we have created a single, future-ready ecosystem. This model creates the foundation for predictive, preventive and personalised future of health, resulting in earlier intervention at population scale that builds a healthier community. This partnership reflects Abu Dhabi's competitive advantage, positioning the Emirate as a premier global hub to build, test and scale the next generation of life sciences innovation." Albarah El-Khani, Chief Operating Officer, Integrated Health Solutions, M42 said, "This collaboration is a powerful example of how advanced biobanking infrastructure can be directly connected to enable earlier detection, personalized prevention and therapeutic innovation. Abu Dhabi Biobank provides not only access to high-quality biological materials, but also to data, governance and translational pathways. We are committed to advancing precision medicine through world-class biobanking, data infrastructure and innovation. BioTwin supports this ambition with its cutting-edge tech platform to enable earlier detection, personalized prevention and future-ready healthcare models across the UAE." The partnership creates a foundation for future clinical, operational and commercial deployment opportunities in Abu Dhabi, starting with early detection and expanding toward broader applications in preventive health, health optimization and personalized care. Louis-Philippe Noel, Founder and Chief Executive Officer of BioTwin said,"This partnership with the Abu Dhabi Biobank represents a major step in BioTwin's mission to make early detection, prevention and personalised health optimisation accessible through Human Virtual Twin technology. Abu Dhabi is building one of the most advanced precision health ecosystems in the world. Together with Abu Dhabi Biobank, we have the opportunity to expand a technology platform that can support earlier insight, longitudinal health monitoring and a more proactive model of care." BioTwin's platform combines home-based dried blood spot collection, multi-biomarker analysis and AI-enabled Human Virtual Twin modeling to help generate longitudinal insights into individual health trajectories.